fda compounding semaglutide news alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA warns about compounded versions

Mounjaro, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight and maintain their weight loss, according to a study published Monday in JAMA Internal Medicine

99: 15901595 [DOI] [PubMed] [Google Scholar] 142.Ding KH, Zhong Q, Xie D, et al

Supporting skin quality and elasticity while the body is actively changing can make a meaningful difference in how well the skin rebounds over time

The evidence suggests that tirzepatides dual-receptor mechanism offers enhanced weight loss and metabolic benefits for many patients

Furthermore, telehealth platforms limit a providers ability to perform objective assessments throughout pharmacotherapy

GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity, but their mechanism of delaying gastric emptying presents important clinical considerations